(Q27853239)

13 November 2016

title

An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib (English)

1 reference

Smoothened variants explain the majority of drug resistance in basal cell carcinoma

PubMed

PubMed publication ID

13 November 2016

1 reference

ChEBI release 2020-05-28

Christina Danial

1

0 references

Kavita Y Sarin

series ordinal

2

0 references

Anthony E Oro

series ordinal

3

0 references

Anne Lynn S Chang

series ordinal

4

0 references

language of work or name

English

0 references

publication date

15 March 2016

0 references

published in

Clinical Cancer Research

0 references

volume

22

0 references

issue

6

0 references

page(s)

1325-9

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Structure of the human smoothened receptor bound to an antitumour agent

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Activating Smoothened mutations in sporadic basal-cell carcinoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4794361

10.1158/1078-0432.CCR-15-1588

27 November 2018

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

26546616

1 reference